跳到主要內容區塊
Google  

 

 

:::

[2020/03/20] “The TVGH, NYMU, NCTU Alliance” Strives to Assist Mass Production of Antiviral Drugs

“The TVGH, NYMU and NCTU Alliance” is assisting industry to prepare for possible threats from the pandemic

 

National Yang-Ming University, National Chiao Tung University and Taipei Veterans General Hospital have established an alliance in response to the COVID-19 pandemic and signed a cooperation memorandum with two biotechnology companies, SyneuRx and Formosa Laboratories Inc., because of the urgent need for antiviral drugs. Formosa Laboratories is also assessing their capability of producing Remdesivir, a potential anti-Covid-19 drug, which ought to come into mass production after authorization.

 

After cooperating with Medigen Vaccine Biologics in the areas of fast-screening reagents and vaccine research, “The Taipei Veterans General Hospital, National Yang-Ming University, National Chiao Tung University Alliance” hopes to combine the capacity of NYMU Biomedicine, NCTU School of Law and the power of TVGH in order to assist industries to prepare for possible threats associated with the pandemic.

 

Formosa Laboratories is a major active pharmaceutical ingredient (API) manufacturer and is one of the few drug companies with ultra-low temperature equipment and the potential to carry out mass production of a drug within a short period of time. Formosa Laboratories remarked that mass production of Remdesivir requires chemical reaction tanks at -78℃ and that one kilogram of API is only able to provide treatment for one thousand patients. Formosa Laboratories has adjusted their production line to be able to make Remdesivir and will be able to generate ten grams of the drug within two weeks, one hundred grams within one month and hundreds of kilograms per year after that. They have also decided that, in response to the need for Remdesivir, they will convert present production lines to make Remdesivir. Eventually, this will be able to provide treatment for about 20,000 patients every month.

 

     

  “The TVGH, NYMU and NCTU Alliance” and Formosa Laboratories have signed a cooperation memorandum and will start mass producing Remdesivir after authorization

 

During past flu epidemics, Taiwan has requested compulsory authorization from the relevant R&D pharmaceutical company holding the original patent in order to produce Tamiflu for domestic needs. This was unprecedented as a means of epidemic prevention and made Taiwan the first country in the world to compulsively authorize Tamiflu. Although Remdesivir is still under clinical investigation, it is a candidate drug for COVID-19 according to WHO. In order to prevent the pandemic from spreading, Taiwan already has developed the ability to produce Remdesivir. As long as the authority to produce the drug happens, Taiwan will be able to protect its people despite a shortage of Remdesivir internationally..

 

According to Article 87 of the Patent Law, in response to a national emergency or another major emergency, the patent agency is able to compulsively authorize release of the required patent rights according to an emergency order or a notice from the National Competent Authorities for Business Objectives and they will notify the patentee of this as soon as possible. According to Article 51 of the Law on Prevention and Control of Infectious Diseases, the central government can purchase medicine and equipment under an emergency program when an epidemic occurs with the relevant documents and inspections being completed within six months. Authorization regulations are complete and based on past experience with Tamiflu, “the TVGH, NYMU and NCTU Alliance” will continue its cooperation with industry, and specialists in biochemistry, pharmacology and law in order to protect the health of Taiwan during the COVID-19 pandemic.

 

 

 

 

 

 

 

 

 


 

views